Please login to the form below

Not currently logged in
Email:
Password:

Astellas files patent suit against Sandoz

Astellas Pharma has filed a lawsuit against generics manufacturer Sandoz relating to a version of Astellas' organ transplantation drug, Prograf, which Sandoz plans to market in Canada

Astellas Pharma has filed a lawsuit against Sandoz, the generic division of Novartis, relating to a version of Astellas' Prograf (tacrolimus hydrate) that Sandoz plans to market in Canada.

The suit, which was filed in the Federal Court of Canada, contains an order prohibiting marketing approval from the Canadian Minister of Health for Sandoz's generic tacrolimus hydrate before the expiration of Astellas' patent for the therapy.

Prograf is currently approved in Canada and elsewhere as an immunosuppressant following organ transplantation.

Sandoz previously launched a generic version of Prograf in the US August 2009.

14th July 2011

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Origins Insights

Origins are part of the Resonant Group. Using novel research methodologies, we dig deeper to deliver authentic audience experiences that...

Latest intelligence

Box 1
Strategic commitment
...
KOL Ambassador Program & Podcast Creation: A Customer Story
...
Animation: Living With
The journey from the patient's perspective...